AR-12: a Novel Broad-spectrum Host-directed Antiviral Drug

PRONIUK, S; DENT, P; MOHR, ML; YOUNT, J; DAMONTE EB; SEPÚLVEDA CS; ZUKIWSKI, A

Roma

Conferencia; 28th International Conference of Antiviral Research; 2015

International Society of Antiviral Research

AR-12 is an orally bioavailable small molecule, with established human safety from a phase I study with long term exposures of up to 33 weeks at dose levels that most likely substantially exceed those required in the antiviral setting. Adverse events reported in this study included fatigue, nausea and skin rash. Using a non-optimized formulation plasma levels of up to 8 µM have been obtained. AR-12 has demonstrated potent broad spectrum in vitro activity primarily in the 0.3-1.2 µM against a range of viruses such as Ebola, Nipah, Lassa, Marburg, Junin, Tacaribe, Yellow Fever, Hepatitis C, Epstein Barr, Venezuelan equine encephalitis, Chikungunya and Influenza (H1N1, H3N2).